Updates are available Correction dated 2021-09-28
Click to view Correction: https://doi.org/10.1007/s13318-021-00719-8
-
Authors
Kareva, Irina http://orcid.org/0000-0003-1100-6806
Zutshi, Anup
Mateo, Cristina Vazquez
Papasouliotis, Orestis
- License Information
-
More Information
Article History
Accepted: 11 July 2021
First Online: 30 July 2021
Change Date: 28 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13318-021-00719-8
Declarations
:
: Writing and critical review of the manuscript: all authors. Study design: IK. Population PK modeling of atacicept: OP. Clinical information on atacicept: CVM.
: This research was supported by EMD Serono Research and Development Institute, Inc., a business of Merck KGaA, Darmstadt, Germany.
: The authors are employees of EMD Serono Research and Development Institute, Inc., a business of Merck KGaA, Darmstadt, Germany. In 2020 Merck out-licensed atacicept to Vera Therapeutics.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Available upon request.
